SCLERODERMA & RAYNAUD'S UK
To promote and support research into the causes, treatment, care and prevention of scleroderma and Raynaud's and related disorders and to disseminate the results of such research; and to advance Education and Awareness of scleroderma and Raynaud's and related disorders, including but not limited to the provision and production of educational literature.
Objects
THE OBJECTS OF THE CIO ARE FOR THE PUBLIC BENEFIT:TO RELIEVE PERSONS SUFFERING FROM AND SUPPORTING PEOPLE LIVING WITH SCLERODERMA AND RAYNAUD'S AND RELATED DISORDERS, INCLUDING BUT NOT LIMITED TO PROVIDING FINANCIAL SUPPORT FOR SUCH PERSONS AND THEIR FAMILIES IN NEED;TO PROMOTE AND SUPPORT RESEARCH INTO THE CAUSES, TREATMENT, CARE AND PREVENTION OF SCLERODERMA AND RAYNAUD'S AND RELATED DISORDERS AND TO DISSEMINATE THE RESULTS OF SUCH RESEARCH; ANDTO ADVANCE EDUCATION AND AWARENESS OF SCLERODERMA AND RAYNAUD'S AND RELATED DISORDERS, INCLUDING BUT NOT LIMITED TO THE PROVISION AND PRODUCTION OF EDUCATIONAL LITERATURE.
Financial health, per its FY2025 accounts
The accounts state that the charity reported a net deficit of £1,044,724 for the year ended 31 March 2025, driven by increased expenditure on research and services. Despite this deficit, the trustees confirm that unrestricted reserves of £3,594,375 are in excess of the stated policy target of approximately £1 million, and there are no material uncertainties regarding the charity's ability to continue as a going concern.
What the accounts disclose
“The subsidiary was registered in England and Wales with registered number 07869668. A decision has been taken to sell the remaining stock and cease trading.” — page 39
Policies the charity declares
- Bullying and harassment policy and procedures
- Campaigns and political activity policy and procedures
- Complaints handling
- Complaints policy and procedures
- Conflicting interests
- Engaging external speakers at charity events policy and procedures
- Financial reserves policy and procedures
- Internal charity financial controls policy and procedures
- Internal risk management policy and procedures
- Investing charity funds policy and procedures
- Investment
- Risk management
- Safeguarding policy and procedures
- Safeguarding vulnerable beneficiaries
- Serious incident reporting policy and procedures
- Social media policy and procedures
- Trustee conflicts of interest policy and procedures
- Trustee expenses policy and procedures
- Volunteer management
From the charity’s annual return (Part A, self-declared)
Self-declared on the annual return for the financial year ending 31/03/2025
- Volunteers: 33
- Employees paid over £60,000: 2 (£60,001–£70,000: 1; £90,001–£100,000: 1)
- Has a trading subsidiary
Self-declared on the annual return for the financial year ending 31/03/2024
- Volunteers: 20
- Employees paid over £60,000: 2 (£60,001–£70,000: 1; £90,001–£100,000: 1)
- Has a trading subsidiary
Self-declared on the annual return for the financial year ending 31/03/2023
- Volunteers: 20
- Employees paid over £60,000: 1 (£80,001–£90,000: 1)
- Has a trading subsidiary
Corporate structure
- Trading subsidiary: RSA TRADING COMPANY LIMITED Companies House 07869668
Structured financials (annual return, FY ending 31/03/2024)
Trustees
- Chris Skeet
- Elliot Grey Dunster
- Jason Anthony Bryant
- Kellie Scott
- Professor Allan Lawrie
- Professor Dorian Haskard
Income and spending
| Financial year end | Income | Spending |
|---|---|---|
| 31/03/2025 | £433k | £1.5m |
| 31/03/2024 | £998k | £1.4m |
| 31/03/2023 | £822k | £1.1m |
| 31/03/2022 | £2.0m | £1.1m |
| 31/03/2021 | £2.3m | £1.2m |
Common questions
Is SCLERODERMA & RAYNAUD'S UK financially healthy?
Per its FY2025 accounts: The accounts state that the charity reported a net deficit of £1,044,724 for the year ended 31 March 2025, driven by increased expenditure on research and services. Despite this deficit, the trustees confirm that unrestricted reserves of £3,594,375 are in excess of the stated policy target of approximately £1 million, and there are no material uncertainties regarding the charity's ability to continue as a going concern. Its FY2025 accounts were audited by Azets Audit Services.
Who funds SCLERODERMA & RAYNAUD'S UK?
Funders whose own accounts filings name SCLERODERMA & RAYNAUD'S UK as a grant recipient include TOM AND SHEILA SPRINGER CHARITY, THE ADINT CHARITABLE TRUST, THE CHARLES LITTLEWOOD HILL TRUST, THE ARDWICK TRUST.
Known funders
| Funder | Year | Amount | Purpose (as stated by the funder) |
|---|---|---|---|
| TOM AND SHEILA SPRINGER CHARITY | FY2022 | £20k | |
| THE ADINT CHARITABLE TRUST | FY2023 | £10k | |
| THE ADINT CHARITABLE TRUST | FY2024 | £5k | |
| TOM AND SHEILA SPRINGER CHARITY | FY2023 | £4k | |
| THE CHARLES LITTLEWOOD HILL TRUST | FY2025 | £1k | |
| THE ARDWICK TRUST | FY2024 | £200 |
Government & lottery funding
| Funder | Date | Amount | Purpose |
|---|---|---|---|
| The National Lottery Community Fund | 19/08/2022 | £10k | SRUK Online Support Programme |
| UK government | 02/10/2020 | £9k | Coronavirus Community Support Fund |
Funders of similar charities
| Funder | Similar charities funded | Amount to them |
|---|---|---|
| THE BARBOUR FOUNDATION | 2 | £6k |
| THE FRANK LITCHFIELD GENERAL CHARITABLE TRUST | 2 | £4k |
| THE STONEYGATE TRUST | 1 | £2.6m |
| THE THOMPSON FAMILY CHARITABLE TRUST | 1 | £345k |
| THE CATHERINE COOKSON CHARITABLE TRUST | 1 | £75k |
| THE WATCHES OF SWITZERLAND GROUP FOUNDATION | 1 | £50k |
| THE KIDNEY FUND | 1 | £40k |
| THE JOSEPH AND LILIAN SULLY FOUNDATION | 1 | £30k |
Charities like this
- THE SKIN CANCER RESEARCH FUND
- SARCOIDOSISUK
- Melanoma UK
- MELANOMA-ME FOUNDATION
- KD-UK, KENNEDY'S DISEASE UK
- KIDNEY RESEARCH UK
Side by side with its peers
| Charity | Income | Top pay band | Staff >£60k | Reserves vs policy | Fundraising cost | Going concern |
|---|---|---|---|---|---|---|
| SCLERODERMA & RAYNAUD'S UK | £433k | — | — | unclear | — | no doubt |
| THE SKIN CANCER RESEARCH FUND | £39k | — | 0 | unclear | 24.8% | no doubt |
| SARCOIDOSISUK | £185k | — | 0 | unclear | — | no doubt |
| Melanoma UK | £212k | — | 0 | above | 2.3% | no doubt |
| MELANOMA-ME FOUNDATION | £161k | — | 0 | above | — | no doubt |
| KD-UK, KENNEDY'S DISEASE UK | £40k | — | 0 | unclear | — | no doubt |